ACC Part 2: The TACT2 trial of chelation, inter-atrial shunts for HF, and triglyceride lowering; plus diltiazem and Factor Xa anticoagulants are the topics John Mandrola, MD, covers this week. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I. TACT 2 Chelation Therapy Provides No Benefit Post-MI https://www.medscape.com/viewarticle/chelation-therapy-provides-no-benefit-post-mi-2024a10006l5 Chelation Therapy and CV Risk: Why TACT2 Showed No Benefit https://www.medscape.com/viewarticle/chelation-therapy-and-cv-risk-why-tact2-showed-no-benefit-2024a1000761?src= <ul> <li>JAMA TACT 1 paper https://jamanetwork.com/journals/jama/fullarticle/1672238</li> <li>Diabetes Subgroup paper https://pubmed.ncbi.nlm.nih.gov/24254885/</li> <li>A New Look at P-values https://evidence.nejm.org/doi/abs/10.1056/EVIDoa2300003</li> <li>PARAGON HF https://www.nejm.org/doi/full/10.1056/NEJMoa1908655</li> </ul> II. Interatrial Shunts for HF No Net HF Benefit for Interarterial Shunt Device https://www.medscape.com/viewarticle/no-net-hf-benefit-interarterial-shunt-device-2024a10006kk <ul> <li>REDUCE LAP HF II https://doi.org/10.1016/S0140-6736(22)00016-2</li> </ul> III. Triglyceride Lowering Early Olezarsen Results Show 50% Reduction in Triglycerides https://www.medscape.com/viewarticle/early-olezarsen-results-show-50-reduction-triglycerides-2024a10006oz Is It Time to Stop Treating High Triglycerides? https://www.medscape.com/viewarticle/990126 <ul> <li>NEJM https://www.nejm.org/doi/full/10.1056/NEJMoa2402309</li> </ul> Substantial Triglyceride Reduction With Plozasiran https://www.medscape.com/viewarticle/substantial-triglyceride-reduction-plozasiran-2024a10006wf?icd=login_success_email_match_norm <ul> <li>JAMA Cardiology https://jamanetwork.com/journals/jamacardiology/article-abstract/2817469</li> </ul> IV. Diltiazem and Factor Xa inhibitors <ul> <li>JAMA Vanderbilt University Paper https://jamanetwork.com/journals/jama/fullarticle/2817546</li> </ul> You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net

<description>&lt;p&gt;ACC Part 2: The TACT2 trial of chelation, inter-atrial shunts for HF, and triglyceride lowering; plus diltiazem and Factor Xa anticoagulants are the topics John Mandrola, MD, covers this week.&lt;/p&gt; &lt;p&gt;&lt;em&gt;This podcast is intended for healthcare professionals only&lt;/em&gt;.&lt;/p&gt; &lt;p&gt;To read a partial transcript or to comment, visit:&lt;/p&gt; &lt;p&gt;https://www.medscape.com/twic&lt;/p&gt; &lt;p&gt;&lt;strong&gt;I. TACT 2&lt;/strong&gt;&lt;/p&gt; &lt;p&gt;&lt;strong&gt;Chelation Therapy Provides No Benefit Post-MI&lt;/strong&gt;&lt;/p&gt; &lt;p&gt; &lt;strong&gt;https://www.medscape.com/viewarticle/chelation-therapy-provides-no-benefit-post-mi-2024a10006l5&lt;/strong&gt;&lt;/p&gt; &lt;p&gt;&lt;strong&gt;Chelation Therapy and CV Risk: Why TACT2 Showed No Benefit https://www.medscape.com/viewarticle/chelation-therapy-and-cv-risk-why-tact2-showed-no-benefit-2024a1000761?src=&lt;/strong&gt;&lt;/p&gt; &lt;ul&gt; &lt;li&gt;&lt;strong&gt;JAMA TACT 1 paper https://jamanetwork.com/journals/jama/fullarticle/1672238&lt;/strong&gt;&lt;/li&gt; &lt;li&gt;&lt;strong&gt;Diabetes Subgroup paper https://pubmed.ncbi.nlm.nih.gov/24254885/&lt;/strong&gt;&lt;/li&gt; &lt;li&gt;&lt;strong&gt;A New Look at P-values https://evidence.nejm.org/doi/abs/10.1056/EVIDoa2300003&lt;/strong&gt;&lt;/li&gt; &lt;li&gt;&lt;strong&gt;PARAGON HF https://www.nejm.org/doi/full/10.1056/NEJMoa1908655&lt;/strong&gt;&lt;/li&gt; &lt;/ul&gt; &lt;p&gt;&lt;em&gt;&lt;strong&gt;II. Interatrial Shunts for HF&lt;/strong&gt;&lt;/em&gt;&lt;/p&gt; &lt;p&gt;&lt;strong&gt;No Net HF Benefit for Interarterial Shunt Device&lt;/strong&gt;&lt;/p&gt; &lt;p&gt; &lt;strong&gt;https://www.medscape.com/viewarticle/no-net-hf-benefit-interarterial-shunt-device-2024a10006kk&lt;/strong&gt;&lt;/p&gt; &lt;ul&gt; &lt;li&gt;&lt;strong&gt;REDUCE LAP HF II https://doi.org/10.1016/S0140-6736(22)00016-2&lt;/strong&gt;&lt;/li&gt; &lt;/ul&gt; &lt;p&gt;&lt;em&gt;&lt;strong&gt;III. Triglyceride Lowering&lt;/strong&gt;&lt;/em&gt;&lt;/p&gt; &lt;p&gt;&lt;strong&gt;Early Olezarsen Results Show 50% Reduction in Triglycerides&lt;/strong&gt;&lt;/p&gt; &lt;p&gt; &lt;strong&gt;https://www.medscape.com/viewarticle/early-olezarsen-results-show-50-reduction-triglycerides-2024a10006oz&lt;/strong&gt;&lt;/p&gt; &lt;p&gt;&lt;strong&gt;Is It Time to Stop Treating High Triglycerides?&lt;/strong&gt;&lt;/p&gt; &lt;p&gt;&lt;strong&gt;https://www.medscape.com/viewarticle/990126&lt;/strong&gt;&lt;/p&gt; &lt;ul&gt; &lt;li&gt;&lt;strong&gt;&lt;em&gt;NEJM&lt;/em&gt;&lt;/strong&gt; &lt;strong&gt;https://www.nejm.org/doi/full/10.1056/NEJMoa2402309&lt;/strong&gt;&lt;/li&gt; &lt;/ul&gt; &lt;p&gt;&lt;strong&gt;Substantial Triglyceride Reduction With Plozasiran&lt;/strong&gt;&lt;/p&gt; &lt;p&gt; &lt;strong&gt;https://www.medscape.com/viewarticle/substantial-triglyceride-reduction-plozasiran-2024a10006wf?icd=login_success_email_match_norm&lt;/strong&gt;&lt;/p&gt; &lt;ul&gt; &lt;li&gt;&lt;strong&gt;&lt;em&gt;JAMA Cardiology&lt;/em&gt;&lt;/strong&gt; &lt;strong&gt;https://jamanetwork.com/journals/jamacardiology/article-abstract/2817469&lt;/strong&gt;&lt;/li&gt; &lt;/ul&gt; &lt;p&gt;&lt;em&gt;&lt;strong&gt;IV. Diltiazem and Factor Xa inhibitors&lt;/strong&gt;&lt;/em&gt;&lt;/p&gt; &lt;ul&gt; &lt;li&gt;&lt;em&gt;&lt;strong&gt;JAMA Vanderbilt University Paper&lt;/strong&gt;&lt;/em&gt; &lt;strong&gt;https://jamanetwork.com/journals/jama/fullarticle/2817546&lt;/strong&gt;&lt;/li&gt; &lt;/ul&gt; &lt;p&gt;&lt;em&gt;&lt;strong&gt;You may also like:&lt;/strong&gt;&lt;/em&gt;&lt;/p&gt; &lt;p&gt;The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington&lt;/p&gt; &lt;p&gt;Questions or feedback, please contact news@medscape.net&lt;/p&gt;</description>

ACC Part 2: The TACT2 trial of chelation, inter-atrial shunts for HF, and triglyceride lowering; plus diltiazem and Factor Xa anticoagulants are the topics John Mandrola, MD, covers this week. This podcast is intended for healthcare professionals...

Apr 19 2024 This Week in Cardiology

ACC Recap #1: DanGer Shock (plus a sobering JAMA research letter on Impella use), REDUCE-AMI, PREVENT, and EMPACT-MI are the topics John Mandrola, MD, covers in this week’s podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I. DanGer-Shock Trial Impella CP Improves Survival in STEMI, Cardiogenic Shock https://www.medscape.com/viewarticle/impella-cp-improves-survival-stemi-cardiogenic-shock-2024a10006kz Impella Saves Lives in Cardiogenic Shock, but Patient Selection Key https://www.medscape.com/viewarticle/1000659 <ul> <li>Published DanGer Shock Study  https://www.nejm.org/doi/full/10.1056/NEJMoa2312572</li> <li>JAMA Research letter https://jamanetwork.com/journals/jama/article-abstract/2817457</li> </ul> II. REDUCE-AMI Trial New Data Question Beta-Blockers Post-MI With Preserved EF https://www.medscape.com/viewarticle/new-data-question-beta-blockers-post-mi-preserved-ef-2024a10006y8 Beta-Blockers Post-MI Past Their Expiration Date: REDUCE-AMI https://www.medscape.com/viewarticle/1000663 <ul> <li>REDUCE-AMI paper https://www.nejm.org/doi/full/10.1056/NEJMoa2401479</li> <li>Meta-analysis: Beta Blockers for MI https://doi.org/10.1016/j.amjmed.2014.05.032</li> </ul> III. PREVENT Trial Preventive PCI for Vulnerable Plaques Reduces Cardiac Events https://www.medscape.com/viewarticle/preventive-pci-vulnerable-plaques-reduces-cardiac-events-2024a10006tc Preventive Coronary Stents: Not There Yet https://www.medscape.com/viewarticle/preventive-coronary-stents-not-there-yet-2024a10006yr <ul> <li>PREVENT https://doi.org/10.1016/S0140-6736(24)00413-6</li> </ul> IV. EMPACT MI trial of Empagliflozin in the Post-MI setting Empagliflozin Fails to Reduce Events After Acute MI https://www.medscape.com/viewarticle/empagliflozin-fails-reduce-events-after-acute-mi-2024a10006kn <ul> <li>EMPACT-MI: Another SGLT2 Inhibitor Miss in Post-MI Care  https://www.medscape.com/viewarticle/1000684</li> <li>EMPACT MI https://www.nejm.org/doi/10.1056/NEJMoa2314051</li> <li>DAPA MI https://evidence.nejm.org/doi/full/10.1056/EVIDoa2300286</li> <li>PARADISE MI https://www.nejm.org/doi/full/10.1056/NEJMoa2104508</li> <li>Kaul thread https://x.com/kaulcsmc/status/1776611935842165029</li> <li>Kaul paper https://www.ahajournals.org/doi/full/10.1161/circulationaha.116.022537</li> </ul> You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net

<description>&lt;p&gt;ACC Recap #1: DanGer Shock (plus a sobering &lt;em&gt;JAMA&lt;/em&gt; research letter on Impella use), REDUCE-AMI, PREVENT, and EMPACT-MI are the topics John Mandrola, MD, covers in this week’s podcast.&lt;/p&gt; &lt;p&gt;&lt;em&gt;This podcast is intended for healthcare professionals only&lt;/em&gt;.&lt;/p&gt; &lt;p&gt;To read a partial transcript or to comment, visit:&lt;/p&gt; &lt;p&gt;https://www.medscape.com/twic&lt;/p&gt; &lt;p&gt;&lt;strong&gt;I. DanGer-Shock Trial&lt;/strong&gt;&lt;/p&gt; &lt;p&gt;&lt;strong&gt;Impella CP Improves Survival in STEMI, Cardiogenic Shock https://www.medscape.com/viewarticle/impella-cp-improves-survival-stemi-cardiogenic-shock-2024a10006kz&lt;/strong&gt;&lt;/p&gt; &lt;p&gt;&lt;strong&gt;Impella Saves Lives in Cardiogenic Shock, but Patient Selection Key https://www.medscape.com/viewarticle/1000659&lt;/strong&gt;&lt;/p&gt; &lt;ul&gt; &lt;li&gt;&lt;strong&gt;Published DanGer Shock Study  https://www.nejm.org/doi/full/10.1056/NEJMoa2312572&lt;/strong&gt;&lt;/li&gt; &lt;li&gt;&lt;em&gt;&lt;strong&gt;JAMA Research letter&lt;/strong&gt;&lt;/em&gt; &lt;strong&gt;https://jamanetwork.com/journals/jama/article-abstract/2817457&lt;/strong&gt;&lt;/li&gt; &lt;/ul&gt; &lt;p&gt;&lt;em&gt;&lt;strong&gt;II.&lt;/strong&gt;&lt;/em&gt; &lt;strong&gt;REDUCE-AMI Trial&lt;/strong&gt;&lt;/p&gt; &lt;p&gt;&lt;strong&gt;New Data Question Beta-Blockers Post-MI With Preserved EF https://www.medscape.com/viewarticle/new-data-question-beta-blockers-post-mi-preserved-ef-2024a10006y8&lt;/strong&gt;&lt;/p&gt; &lt;p&gt;&lt;strong&gt;Beta-Blockers Post-MI Past Their Expiration Date: REDUCE-AMI https://www.medscape.com/viewarticle/1000663&lt;/strong&gt;&lt;/p&gt; &lt;ul&gt; &lt;li&gt;&lt;strong&gt;REDUCE-AMI paper&lt;/strong&gt; &lt;strong&gt;https://www.nejm.org/doi/full/10.1056/NEJMoa2401479&lt;/strong&gt;&lt;/li&gt; &lt;li&gt;&lt;strong&gt;Meta-analysis: Beta Blockers for MI&lt;/strong&gt; &lt;strong&gt;https://doi.org/10.1016/j.amjmed.2014.05.032&lt;/strong&gt;&lt;/li&gt; &lt;/ul&gt; &lt;p&gt;&lt;em&gt;&lt;strong&gt;III.&lt;/strong&gt;&lt;/em&gt; &lt;strong&gt;PREVENT Trial&lt;/strong&gt;&lt;/p&gt; &lt;p&gt;&lt;strong&gt;Preventive PCI for Vulnerable Plaques Reduces Cardiac Events&lt;/strong&gt;&lt;/p&gt; &lt;p&gt; &lt;strong&gt;https://www.medscape.com/viewarticle/preventive-pci-vulnerable-plaques-reduces-cardiac-events-2024a10006tc&lt;/strong&gt;&lt;/p&gt; &lt;p&gt;&lt;strong&gt;Preventive Coronary Stents: Not There Yet&lt;/strong&gt;&lt;/p&gt; &lt;p&gt; &lt;strong&gt;https://www.medscape.com/viewarticle/preventive-coronary-stents-not-there-yet-2024a10006yr&lt;/strong&gt;&lt;/p&gt; &lt;ul&gt; &lt;li&gt;&lt;strong&gt;PREVENT&lt;/strong&gt; &lt;strong&gt;https://doi.org/10.1016/S0140-6736(24)00413-6&lt;/strong&gt;&lt;/li&gt; &lt;/ul&gt; &lt;p&gt;&lt;strong&gt;IV. EMPACT MI trial of Empagliflozin in the Post-MI setting&lt;/strong&gt;&lt;/p&gt; &lt;p&gt;&lt;strong&gt;Empagliflozin Fails to Reduce Events After Acute MI&lt;/strong&gt;&lt;/p&gt; &lt;p&gt; &lt;strong&gt;https://www.medscape.com/viewarticle/empagliflozin-fails-reduce-events-after-acute-mi-2024a10006kn&lt;/strong&gt;&lt;/p&gt; &lt;ul&gt; &lt;li&gt;&lt;strong&gt;EMPACT-MI: Another SGLT2 Inhibitor Miss in Post-MI Care  https://www.medscape.com/viewarticle/1000684&lt;/strong&gt;&lt;/li&gt; &lt;li&gt;&lt;strong&gt;EMPACT MI https://www.nejm.org/doi/10.1056/NEJMoa2314051&lt;/strong&gt;&lt;/li&gt; &lt;li&gt;&lt;strong&gt;DAPA MI https://evidence.nejm.org/doi/full/10.1056/EVIDoa2300286&lt;/strong&gt;&lt;/li&gt; &lt;li&gt;&lt;strong&gt;PARADISE MI https://www.nejm.org/doi/full/10.1056/NEJMoa2104508&lt;/strong&gt;&lt;/li&gt; &lt;li&gt;&lt;strong&gt;Kaul thread https://x.com/kaulcsmc/status/1776611935842165029&lt;/strong&gt;&lt;/li&gt; &lt;li&gt;&lt;strong&gt;Kaul paper https://www.ahajournals.org/doi/full/10.1161/circulationaha.116.022537&lt;/strong&gt;&lt;/li&gt; &lt;/ul&gt; &lt;p&gt;&lt;em&gt;&lt;strong&gt;You may also like:&lt;/strong&gt;&lt;/em&gt;&lt;/p&gt; &lt;p&gt;The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington&lt;/p&gt; &lt;p&gt;Questions or feedback, please contact news@medscape.net&lt;/p&gt;</description>

ACC Recap #1: DanGer Shock (plus a sobering JAMA research letter on Impella use), REDUCE-AMI, PREVENT, and EMPACT-MI are the topics John Mandrola, MD, covers in this week’s podcast. This podcast is intended for healthcare professionals only. To...

Apr 12 2024 This Week in Cardiology

Statins and diabetes, AAD in patients with heart disease, tricuspid valve interventions, and an ACC preview are the topics John Mandrola, MD, discusses in this week’s podcast.This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I. Statins and Diabetes <ul> <li>Meta-analysis in Lancet-Diabetes https://doi.org/10.1016/S2213-8587(24)00040-8</li> <li>Editorial https://doi.org/10.1016/S2213-8587(24)00059-7</li> <li>NEJM Paper on Gene Variants and DM https://www.nejm.org/doi/full/10.1056/nejmoa1604304</li> <li>JAMA Paper on Gene Variants and DM https://jamanetwork.com/journals/jama/fullarticle/2565289</li> </ul> II. Anti-arrhythmic Drugs in Patients With Serious Heart Disease <ul> <li>UPenn Paper on AADs for PVC Suppression https://doi.org/10.1016/j.jacep.2024.01.021</li> <li>Three Questions for Evidence-Based Cardiac EP https://www.ahajournals.org/doi/full/10.1161/circoutcomes.110.957381</li> <li>CAST trial https://www.nejm.org/doi/full/10.1056/NEJM199103213241201</li> </ul> III. Tricuspid Valve Interventions FDA Clears TriClip for Tricuspid Regurgitation https://www.medscape.com/viewarticle/fda-clears-triclip-tricuspid-regurgitation-2024a100068o FDA Panel in Favor of TriClip for Tricuspid Regurgitation https://www.medscape.com/viewarticle/fda-panel-favor-triclip-tricuspid-regurgitation-2024a100037n <ul> <li>Slides for Trisend II</li> <li>TRILUMINATE https://www.nejm.org/doi/full/10.1056/NEJMoa2300525</li> </ul> IV. ACC Preview Mandrola's Three Trials to Look for at the 2024 American College of Cardiology Scientific Sessions https://www.medscape.com/viewarticle/1000613 You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net

<description>&lt;p&gt;Statins and diabetes, AAD in patients with heart disease, tricuspid valve interventions, and an ACC preview are the topics John Mandrola, MD, discusses in this week’s podcast.&lt;em&gt;This podcast is intended for healthcare professionals only&lt;/em&gt;.&lt;/p&gt; &lt;p&gt;To read a partial transcript or to comment, visit:&lt;/p&gt; &lt;p&gt;https://www.medscape.com/twic&lt;/p&gt; &lt;p&gt;&lt;strong&gt;I. Statins and Diabetes&lt;/strong&gt;&lt;/p&gt; &lt;ul&gt; &lt;li&gt;&lt;strong&gt;Meta-analysis in &lt;em&gt;Lancet-Diabetes&lt;/em&gt; https://doi.org/10.1016/S2213-8587(24)00040-8&lt;/strong&gt;&lt;/li&gt; &lt;li&gt;&lt;strong&gt;Editorial https://doi.org/10.1016/S2213-8587(24)00059-7&lt;/strong&gt;&lt;/li&gt; &lt;li&gt;&lt;strong&gt;&lt;em&gt;NEJM&lt;/em&gt; Paper on Gene Variants and DM https://www.nejm.org/doi/full/10.1056/nejmoa1604304&lt;/strong&gt;&lt;/li&gt; &lt;li&gt;&lt;strong&gt;&lt;em&gt;JAMA&lt;/em&gt; Paper on Gene Variants and DM https://jamanetwork.com/journals/jama/fullarticle/2565289&lt;/strong&gt;&lt;/li&gt; &lt;/ul&gt; &lt;p&gt;&lt;em&gt;&lt;strong&gt;II. Anti-arrhythmic Drugs in Patients With Serious Heart Disease&lt;/strong&gt;&lt;/em&gt;&lt;/p&gt; &lt;ul&gt; &lt;li&gt;&lt;strong&gt;UPenn Paper on AADs for PVC Suppression https://doi.org/10.1016/j.jacep.2024.01.021&lt;/strong&gt;&lt;/li&gt; &lt;li&gt;&lt;strong&gt;Three Questions for Evidence-Based Cardiac EP https://www.ahajournals.org/doi/full/10.1161/circoutcomes.110.957381&lt;/strong&gt;&lt;/li&gt; &lt;li&gt;&lt;strong&gt;CAST trial https://www.nejm.org/doi/full/10.1056/NEJM199103213241201&lt;/strong&gt;&lt;/li&gt; &lt;/ul&gt; &lt;p&gt;&lt;em&gt;&lt;strong&gt;III. Tricuspid Valve Interventions&lt;/strong&gt;&lt;/em&gt;&lt;/p&gt; &lt;p&gt;&lt;strong&gt;FDA Clears TriClip for Tricuspid Regurgitation&lt;/strong&gt;&lt;/p&gt; &lt;p&gt; &lt;strong&gt;https://www.medscape.com/viewarticle/fda-clears-triclip-tricuspid-regurgitation-2024a100068o&lt;/strong&gt;&lt;/p&gt; &lt;p&gt;&lt;strong&gt;FDA Panel in Favor of TriClip for Tricuspid Regurgitation&lt;/strong&gt;&lt;/p&gt; &lt;p&gt; &lt;strong&gt;https://www.medscape.com/viewarticle/fda-panel-favor-triclip-tricuspid-regurgitation-2024a100037n&lt;/strong&gt;&lt;/p&gt; &lt;ul&gt; &lt;li&gt;&lt;strong&gt;Slides for Trisend II&lt;/strong&gt;&lt;/li&gt; &lt;li&gt;&lt;strong&gt;TRILUMINATE https://www.nejm.org/doi/full/10.1056/NEJMoa2300525&lt;/strong&gt;&lt;/li&gt; &lt;/ul&gt; &lt;p&gt;&lt;em&gt;&lt;strong&gt;IV. ACC Preview&lt;/strong&gt;&lt;/em&gt;&lt;/p&gt; &lt;p&gt;&lt;strong&gt;Mandrola's Three Trials to Look for at the 2024 American College of Cardiology Scientific Sessions&lt;/strong&gt;&lt;/p&gt; &lt;p&gt; &lt;strong&gt;https://www.medscape.com/viewarticle/1000613&lt;/strong&gt;&lt;/p&gt; &lt;p&gt;&lt;em&gt;&lt;strong&gt;You may also like:&lt;/strong&gt;&lt;/em&gt;&lt;/p&gt; &lt;p&gt;The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington&lt;/p&gt; &lt;p&gt;Questions or feedback, please contact news@medscape.net&lt;/p&gt;</description>

Statins and diabetes, AAD in patients with heart disease, tricuspid valve interventions, and an ACC preview are the topics John Mandrola, MD, discusses in this week’s podcast.This podcast is intended for healthcare professionals only. To read a...

Apr 05 2024 This Week in Cardiology

Intermittent fasting, anticoagulation decisions, heterogenous treatment effects, frailty in HF, the importance of the ECG, and industry conflicts are the topics John Mandrola, MD, covers this week. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I. Intermittent Fasting No, Intermittent Fasting Won't Kill You https://www.medscape.com/viewarticle/1000544 <ul> <li>NEJM Paper on Time-Restricted Eating  https://www.nejm.org/doi/full/10.1056/NEJMoa2114833</li> <li>JAMA TREAT Clinical Trial https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2771095</li> </ul> II. Stroke Prevention with OAC <ul> <li>Shah Meta analysis of Vitamin K Agonists in AF https://www.ahajournals.org/doi/abs/10.1161/CIRCOUTCOMES.123.010269</li> </ul> III. Heterogenous Treatment Effects in Trials Pivotal CV Trials May Not Apply to Complex Patients https://www.medscape.com/viewarticle/989129 <ul> <li>Analysis of 8 Trials of Multimorbidity and Treatment Response https://doi.org/10.1016/j.amjmed.2024.01.028</li> </ul> IV. Frailty and HF <ul> <li>Circulation Outcomes: Multidomain Frailty and Mode of Death in HF  https://www.ahajournals.org/doi/10.1161/CIRCOUTCOMES.123.010416</li> </ul> V. ECG in LBBB <ul> <li>JAMA Cardiology: Revised Definition of LBBB  https://jamanetwork.com/journals/jamacardiology/fullarticle/2816973</li> </ul> VI. Industry Payments to Doctors <ul> <li>JAMA: Payments to US Physicians by Specialty https://jamanetwork.com/journals/jama/fullarticle/2816900</li> </ul> You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net

<description>&lt;p&gt;Intermittent fasting, anticoagulation decisions, heterogenous treatment effects, frailty in HF, the importance of the ECG, and industry conflicts are the topics John Mandrola, MD, covers this week.&lt;/p&gt; &lt;p&gt;&lt;em&gt;This podcast is intended for healthcare professionals only&lt;/em&gt;. To read a partial transcript or to comment, visit:&lt;/p&gt; &lt;p&gt;https://www.medscape.com/twic&lt;/p&gt; &lt;p&gt;&lt;strong&gt;I. Intermittent Fasting&lt;/strong&gt;&lt;/p&gt; &lt;p&gt;&lt;strong&gt;No, Intermittent Fasting Won't Kill You&lt;/strong&gt;&lt;/p&gt; &lt;p&gt; &lt;strong&gt;https://www.medscape.com/viewarticle/1000544&lt;/strong&gt;&lt;/p&gt; &lt;ul&gt; &lt;li&gt;&lt;em&gt;&lt;strong&gt;NEJM Paper on Time-Restricted Eating  &lt;/strong&gt;&lt;/em&gt;&lt;strong&gt;https://www.nejm.org/doi/full/10.1056/NEJMoa2114833&lt;/strong&gt;&lt;/li&gt; &lt;li&gt;&lt;em&gt;&lt;strong&gt;JAMA TREAT Clinical Trial&lt;/strong&gt;&lt;/em&gt; &lt;strong&gt;https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2771095&lt;/strong&gt;&lt;/li&gt; &lt;/ul&gt; &lt;p&gt;&lt;em&gt;&lt;strong&gt;II. Stroke Prevention with OAC&lt;/strong&gt;&lt;/em&gt;&lt;/p&gt; &lt;ul&gt; &lt;li&gt;&lt;em&gt;&lt;strong&gt;Shah Meta analysis of Vitamin K Agonists in AF&lt;/strong&gt;&lt;/em&gt; &lt;strong&gt;https://www.ahajournals.org/doi/abs/10.1161/CIRCOUTCOMES.123.010269&lt;/strong&gt;&lt;/li&gt; &lt;/ul&gt; &lt;p&gt;&lt;em&gt;&lt;strong&gt;III. Heterogenous Treatment Effects in Trials&lt;/strong&gt;&lt;/em&gt;&lt;/p&gt; &lt;p&gt;&lt;strong&gt;Pivotal CV Trials May Not Apply to Complex Patients&lt;/strong&gt;&lt;/p&gt; &lt;p&gt;&lt;strong&gt;https://www.medscape.com/viewarticle/989129&lt;/strong&gt;&lt;/p&gt; &lt;ul&gt; &lt;li&gt;&lt;strong&gt;An&lt;/strong&gt;&lt;strong&gt;alysis of 8 Trials of Multimorbidity and Treatment Response&lt;/strong&gt; &lt;strong&gt;https://doi.org/10.1016/j.amjmed.2024.01.028&lt;/strong&gt;&lt;/li&gt; &lt;/ul&gt; &lt;p&gt;&lt;em&gt;&lt;strong&gt;IV. Frailty and HF&lt;/strong&gt;&lt;/em&gt;&lt;/p&gt; &lt;ul&gt; &lt;li&gt;&lt;strong&gt;&lt;em&gt;Circulation Outcomes&lt;/em&gt;&lt;/strong&gt;: Multidomain Frailty and Mode of Death in HF  &lt;strong&gt;https://www.ahajournals.org/doi/10.1161/CIRCOUTCOMES.123.010416&lt;/strong&gt;&lt;/li&gt; &lt;/ul&gt; &lt;p&gt;&lt;strong&gt;V. ECG in LBBB&lt;/strong&gt;&lt;/p&gt; &lt;ul&gt; &lt;li&gt;&lt;strong&gt;&lt;em&gt;JAMA Cardiology:&lt;/em&gt;&lt;/strong&gt; &lt;strong&gt;Revised Definition of LBBB &lt;/strong&gt; &lt;strong&gt;https://jamanetwork.com/journals/jamacardiology/fullarticle/2816973&lt;/strong&gt;&lt;/li&gt; &lt;/ul&gt; &lt;p&gt;&lt;strong&gt;VI. Industry Payments to Doctors&lt;/strong&gt;&lt;/p&gt; &lt;ul&gt; &lt;li&gt;&lt;strong&gt;&lt;em&gt;JAMA:&lt;/em&gt;&lt;/strong&gt; &lt;strong&gt;Payments to US Physicians by Specialty&lt;/strong&gt; &lt;strong&gt;https://jamanetwork.com/journals/jama/fullarticle/2816900&lt;/strong&gt;&lt;/li&gt; &lt;/ul&gt; &lt;p&gt;&lt;em&gt;&lt;strong&gt;You may also like:&lt;/strong&gt;&lt;/em&gt;&lt;/p&gt; &lt;p&gt;The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington&lt;/p&gt; &lt;p&gt;Questions or feedback, please contact news@medscape.net&lt;/p&gt;</description>

Intermittent fasting, anticoagulation decisions, heterogenous treatment effects, frailty in HF, the importance of the ECG, and industry conflicts are the topics John Mandrola, MD, covers this week. This podcast is intended for...

Mar 29, 2024 This Week in Cardiology Podcast

p>Obesity drugs as ASCVD-modifiers, HR monitors, when journals publish obvious facts, and effect scores and sorting out signals from RCTs are the topics John Mandrola, MD, covers in this week's podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I. Denmark Notes II. FDA approval of Semaglutide FDA Approves Semaglutide for Cardiovascular Risk Reduction https://www.medscape.com/viewarticle/fda-approves-semaglutide-cardiovascular-risk-reduction-2024a10004ix <ul> <li>Select Trial</li> </ul> III. PPG Monitor Accuracy <ul> <li>Research Letter https://doi.org/10.1016/j.jacc.2024.01.024</li> </ul> IV. AAD and Bradycardia Anti-arrhythmic Drugs Linked to Bradycardia in Patients With AF https://www.medscape.com/viewarticle/anti-arrhythmic-drugs-linked-bradycardia-patients-af-2024a10004vw <ul> <li>JACC paper on AAD Adverse Effects https://doi.org/10.1016/j.jacc.2024.01.013</li> </ul> V. Finding Signals in RCTs   <ul> <li>JAMA paper on Treatment Effects of Oxygen Targets</li> <li>DANISH trial https://www.nejm.org/doi/full/10.1056/nejmoa1608029</li> <li>LAFFLIN et al. Scoring System to Assess Generalizability of Trial Results https://doi.org/10.1177/2047487318815967</li> </ul> You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net

<description>&lt;p&gt;p&gt;Obesity drugs as ASCVD-modifiers, HR monitors, when journals publish obvious facts, and effect scores and sorting out signals from RCTs are the topics John Mandrola, MD, covers in this week's podcast.&lt;/p&gt; &lt;p&gt;&lt;em&gt;This podcast is intended for healthcare professionals only&lt;/em&gt;.&lt;/p&gt; &lt;p&gt;To read a partial transcript or to comment, visit:&lt;/p&gt; &lt;p&gt;https://www.medscape.com/twic&lt;/p&gt; &lt;p&gt;&lt;strong&gt;I. Denmark Notes&lt;/strong&gt;&lt;/p&gt; &lt;p&gt;&lt;strong&gt;II. FDA approval of Semaglutide&lt;/strong&gt;&lt;/p&gt; &lt;p&gt;&lt;strong&gt;FDA Approves Semaglutide for Cardiovascular Risk Reduction&lt;/strong&gt;&lt;/p&gt; &lt;p&gt; &lt;strong&gt;https://www.medscape.com/viewarticle/fda-approves-semaglutide-cardiovascular-risk-reduction-2024a10004ix&lt;/strong&gt;&lt;/p&gt; &lt;ul&gt; &lt;li&gt;&lt;strong&gt;Select Trial&lt;/strong&gt;&lt;/li&gt; &lt;/ul&gt; &lt;p&gt;&lt;strong&gt;III. PPG Monitor Accuracy&lt;/strong&gt;&lt;/p&gt; &lt;ul&gt; &lt;li&gt;&lt;strong&gt;Research Letter https://doi.org/10.1016/j.jacc.2024.01.024&lt;/strong&gt;&lt;/li&gt; &lt;/ul&gt; &lt;p&gt;&lt;strong&gt;IV. AAD and Bradycardia&lt;/strong&gt;&lt;/p&gt; &lt;p&gt;&lt;strong&gt;Anti-arrhythmic Drugs Linked to Bradycardia in Patients With AF&lt;/strong&gt;&lt;/p&gt; &lt;p&gt; &lt;strong&gt;https://www.medscape.com/viewarticle/anti-arrhythmic-drugs-linked-bradycardia-patients-af-2024a10004vw&lt;/strong&gt;&lt;/p&gt; &lt;ul&gt; &lt;li&gt;&lt;strong&gt;&lt;em&gt;JACC&lt;/em&gt;&lt;/strong&gt; &lt;strong&gt;paper on AAD Adverse Effects https://doi.org/10.1016/j.jacc.2024.01.013&lt;/strong&gt;&lt;/li&gt; &lt;/ul&gt; &lt;p&gt;&lt;em&gt;&lt;strong&gt;V. Finding Signals in RCTs&lt;/strong&gt;&lt;/em&gt;&lt;br /&gt;  &lt;/p&gt; &lt;ul&gt; &lt;li&gt;&lt;strong&gt;&lt;em&gt;JAMA&lt;/em&gt;&lt;/strong&gt; &lt;strong&gt;paper &lt;em&gt;on Treatment Effects of Oxygen Targets&lt;/em&gt;&lt;/strong&gt;&lt;/li&gt; &lt;li&gt;&lt;strong&gt;DANISH trial&lt;/strong&gt; &lt;strong&gt;https://www.nejm.org/doi/full/10.1056/nejmoa1608029&lt;/strong&gt;&lt;/li&gt; &lt;li&gt;&lt;strong&gt;LAFFLIN et al. Scoring System to Assess Generalizability of Trial Results https://doi.org/10.1177/2047487318815967&lt;/strong&gt;&lt;/li&gt; &lt;/ul&gt; &lt;p&gt;&lt;em&gt;&lt;strong&gt;You may also like:&lt;/strong&gt;&lt;/em&gt;&lt;/p&gt; &lt;p&gt;The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington&lt;/p&gt; &lt;p&gt;Questions or feedback, please contact news@medscape.net&lt;/p&gt;</description>

p>Obesity drugs as ASCVD-modifiers, HR monitors, when journals publish obvious facts, and effect scores and sorting out signals from RCTs are the topics John Mandrola, MD, covers in this week's podcast. This podcast is intended for healthcare...

Mar 22 2024 This Week in Cardiology

This podcast delivers Dr. John Mandrola’s summary and perspective on top news of the week that cardiologists can’t miss. This podcast is intended for US health professionals only.

This Week in Cardiology

Details

Recent Episodes